The American Journal of Medicine
Volume 121, Issue 3 , Pages 171-178 , March 2008

Antiplatelet Therapy for Postdischarge Medical Management of Acute Coronary Syndrome

  • David Faxon

      Affiliations

    • Department of Medicine, Brigham and Women’s Hospital, Boston, Mass
    • Corresponding Author InformationRequests for reprints should be addressed to David Faxon, MD, Harvard Medical School, Brigham & Women’s Hospital, General Medicine-BC3-Rm012P, 1620 Tremont Street, Boston MA, 02120.
    • ,
  • Marie Brown

      Affiliations

    • Department of Internal Medicine, Rush University Medical Center, Chicago, Ill.

References 

  1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update (A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee). Circulation. 2007;115:e69–e171
  2. Taneja AK, Collinson J, Flather MD, et al. Mortality following non-ST elevation acute coronary syndrome: 4 years follow-up of the PRAIS UK Registry (Prospective Registry of Acute Ischaemic Syndromes in the UK). Eur Heart J. 2004;25:2013–2018
  3. Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither (The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group). BMJ. 1998;316:1337–1343
  4. Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2004;148:263–268
  5. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–1717
  6. Steinhubl SR, Moliterno DJ. The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs. 2005;5:399–408
  7. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110:e82–e292
  8. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002;136:157–160
  9. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  10. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682–1687
  11. Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:513S–548S
  12. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116:e148–e304
  13. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363–2372
  14. Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Dent Assoc. 2007;138:652–655
  15. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366–1374
  16. U.S. Food and Drug Administration. FDA statement on coronary drug-eluting stents (September 14, 2006), Vol 2007. 2006;
  17. Lecompte T, Hardy JF. Antiplatelet agents and perioperative bleeding. Can J Anaesth. 2006;53:S103–S112
  18. Ferguson JJ. The role of oral antiplatelet agents in atherothrombotic disease. Am J Cardiovasc Drugs. 2006;6:149–157
  19. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502
  20. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339
  21. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–533
  22. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–2420
  23. Zeymer U, Gitt AK, Junger C, et al. Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. Eur Heart J. 2006;27:2661–2666
  24. Hodgson JM, Stone GW, Michael Lincoff A, et al. Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the society for cardiovascular angiography and interventions drug-eluting stent task force. Catheter Cardiovasc Interv. 2007;69:327–333
  25. Ong ATL, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088–2092
  26. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006;98:352–356
  27. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–2130
  28. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584–2591
  29. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297:159–168
  30. U.S. Food and Drug Administration. Update to FDA statement on coronary drug-eluting stents, Vol 2007.
  31. Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:e166–e286
  32. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–189
  33. CRUSADE National Quality Initiative, Vol 2007.
  34. Spencer F, Scleparis G, Goldberg RJ, et al. Decade-long trends (1986 to 1997) in the medical treatment of patients with acute myocardial infarction: a community-wide perspective. Am Heart J. 2001;142:594–603
  35. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41:56–61
  36. Kramer JM, Fetterolf D, Charde JP, et al. National evaluation of long-term adherence to beta-blocker therapy after acute myocardial infarction in patients with commercial health insurance. J Am Coll Cardiol. 2004;43:415a–416a
  37. Steinberg BA, Steg PG, Bhatt DL, et al. Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry). Am J Cardiol. 2007;99:1212–1215
  38. Hirsch AT, Bhatt DL, McBride PE, et al. Global risk factors and treatment intensity in elderly patients with atherosclerosis: the experience of the international REACH registry. J Am Coll Cardiol. 2006;47:168A
  39. Mehta RH, Roe MT, Chen AY, et al. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med. 2006;166:2027–2034
  40. CRUSADE National Quality Initiative. 2006 CRUSADE 2nd Quarter Results, Vol 2007.
  41. Calvin JE, Roe MT, Chen A, et al. Higher mortality and less evidence-based therapies among Medicaid-insured patients with high-risk acute coronary syndromes: Results from CRUSADE. J Am Coll Cardiol. 2004;43:413a
  42. LaBresh KA, Ellrodt AG, Gliklich R, et al. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004;164:203–209
  43. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) Initiative. JAMA. 2002;287:1269–1276
  44. Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2001;161:1621–1628
  45. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases (American Heart Association Science Advisory and Coordinating Committee). Circulation. 2002;106:388–391
  46. CRUSADE National Quality Initiative: MAINTAIN CRUSADE: Medication Applied and Sustained Over Time. A Longitudinal Follow-Up Study of the CRUSADE Quality Improvement Initiative, Vol 2007.

PII: S0002-9343(07)01137-0

doi: 10.1016/j.amjmed.2007.09.026

The American Journal of Medicine
Volume 121, Issue 3 , Pages 171-178 , March 2008

Article Tools

* Image Usage & Resolution